Giv­ing first glimpse of da­ta, Scan­cell looks for Covid-19 vac­cine part­ner

UK-based biotech Scan­cell is lift­ing the veil off a Phase I tri­al for its Covid-19 vac­cine, but it’ll al­so be mak­ing a piv­ot on the vac­cine’s strat­e­gy.

Scan­cell said in a re­lease on Mon­day that it is pre­sent­ing the pre­lim­i­nary da­ta from its Phase I clin­i­cal tri­al, which was con­duct­ed at the Uni­ver­si­ty of Cape Town Lung In­stitue in South Africa. The tri­al was in­tend­ed to look at two of vac­cine Scan­cell’s can­di­dates, SCOV1 and SCOV2, in pa­tients be­fore test­ing them as a boost­er. Ac­cord­ing to the biotech, both can­di­dates are plas­mid DNA-based vac­cines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER